Sampre Nutritions Limited, a leading confectionery manufacturer, has entered into a manufacturing agreement with Tolaram Wellness Ltd., Nigeria.
Under the agreement, Sampre will manufacture and supply nutraceutical and food products as per agreed specifications and quality standards. The deal is expected to generate ₹10 crore annually, amounting to ₹30 crore over three years.
Payment terms include 50% advance and balance on dispatch, with transportation costs borne by Tolaram Wellness.
On August 19, 2025, Sampre signed another three-year manufacturing agreement with Rama Exports for nutraceutical and food products. The contract, valued at ₹15 crore, requires Sampre to handle manufacturing, supply, quality assurance, and packaging in line with brand specifications and trademarks. This agreement further reinforces the company’s operational depth and focus on long-term partnerships.
For Q1FY26, Sampre Nutritions reported revenue from operations of ₹10.87 crore, a 141% year-on-year increase compared to ₹4.51 crore in Q1FY25. Net profit stood at ₹70.76 lakh, reflecting a 615% rise from ₹9.89 lakh a year earlier. Earnings Per Share (EPS) improved to ₹0.34 compared to ₹0.11 in the previous year.
The company has also proposed a fundraising initiative through preferential issue, qualified institutional placement (QIP), and public or private offerings. A board meeting will be held to seek shareholder approval for the proposed capital raise. This step aims to strengthen Sampre’s financial position and support its ongoing expansion and diversification plans.
On Monday, Sampre Nutritions' share price locked in a 2% upper circuit at ₹80.09 per share.
Sampre Nutritions Limited's stock has delivered multibagger returns of 161% in the last 50 trading sessions. It has maintained a winning streak for 55 consecutive days, hitting back-to-back upper circuits. From a 52-week low of ₹20.90, the stock price has given 275.13% returns.
Disclaimer: The article is for informational purposes only and not investment advice.
For android only